Resistance is Futile: The Lure of Infectious Disease Investing
The comparatively low-risk opportunity in antibiotics is quite attractive to VCs. But the risk reduction comes with a price--lower returns.
The comparatively low-risk opportunity in antibiotics is quite attractive to VCs. But the risk reduction comes with a price--lower returns.